TY - JOUR
T1 - European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
AU - Frisoni, Giovanni B.
AU - Festari, Cristina
AU - Massa, Federico
AU - Cotta Ramusino, Matteo
AU - Orini, Stefania
AU - Aarsland, Dag
AU - Agosta, Federica
AU - Babiloni, Claudio
AU - Borroni, Barbara
AU - Cappa, Stefano F.
AU - Frederiksen, Kristian S.
AU - Froelich, Lutz
AU - Garibotto, Valentina
AU - Haliassos, Alexander
AU - Jessen, Frank
AU - Kamondi, Anita
AU - Kessels, Roy P. C.
AU - Morbelli, Silvia D.
AU - O'Brien, John T.
AU - Otto, Markus
AU - Perret-Liaudet, Armand
AU - Pizzini, Francesca B.
AU - Vandenbulcke, Mathieu
AU - Vanninen, Ritva
AU - Verhey, Frans
AU - Vernooij, Meike W.
AU - Yousry, Tarek
AU - Boada Rovira, Mercè
AU - Dubois, Bruno
AU - Georges, Jean
AU - Hansson, Oskar
AU - Ritchie, Craig W.
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Nobili, Flavio
N1 - Publisher Copyright: © 2024 Elsevier Ltd
PY - 2024/3/1
Y1 - 2024/3/1
N2 - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
AB - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
UR - http://www.scopus.com/inward/record.url?scp=85185269773&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(23)00447-7
DO - 10.1016/S1474-4422(23)00447-7
M3 - Review article
C2 - 38365381
SN - 1474-4422
VL - 23
SP - 302
EP - 312
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 3
ER -